

Trends in Highly Effective Contraceptive Prescription Patterns in the Canadian Armed Forces

Dr. Janice Ma | Dr. Carlo Rossi | PhD Candidate Bernice Yu 01 February 2023

International Military Women's Health Workshop



Disclaimers

- Ma | Rossi | Yu -> nothing to disclose
- Ma | Rossi | Yu -> no off-label medication usage
- Rossi -> presentation does not reflect endorsement by the Canadian Armed Forces (CAF) or the Canadian Forces Health Services (CFHS)



Canadian Forces

Health Services Group

Background

Why care about contraceptive use?

Reproductive autonomy

Ineffective / inaccessible family planning -> readiness impact

17% of DoD ADSW: menstrual cycles typically interfere with jobs (RAND)

DoD ADSW deployed in the past 24 months who sought contraception prior to deployment, 57% received their preferred birth control method, 37% did not receive any form of birth control through the MHS, and 6% received a nonpreferred method.

Note: contraceptive use / choice not to use are important, and personal, health care decisions for service women; ideally, these choices align with their desires regarding reproductive health and family planning. It is important to recognize that not every service woman wants or needs to use contraception.

Canadian Forces Health Services Group





SARAH O. MEADOWS, REBECCA L. COLLINS, MEGAN S. SCHULER, ROBIN L. BECKMAN, MATTHEW CEFALU

The Women's Reproductive Health Survey (WRHS) of Active-Duty Service Members



TABLE 5.6A

Difficulty Accessing Preferred Birth Control Through the MHS Since Joining the Military, by Service Branch

	DoD Total	Air Force	Army	Marine Corps	Navy	Coast Guard
Ever unable to get preferred birth control through the MHS	18.3% (17.5–19.0)	17.7% ^{d, e} (16.9–18.5)	17.6% ^e (16.2-19.0)	15.3% ^{d, a} (13.1–17.5)	20.4% ^{8, C} (18.8-22.0)	21.0% ^{a, b, c} (19.2–22.8)
Preferred method of birth o	control unable	to obtain				
Birth control pills	41.6%	43.2% ^c	40.6% ^e	31.6% ^{a, e}	42.9%	50.7% ^{b, c}
	(39.4–43.7)	(40.7-45.8)	(36.4-44.9)	(24.4–38.7)	(38.6-47.1)	(45.9–55.5)
Condoms ²	0.7%	0.8%	0.4%	1.0%	0.7%	0.7%
	(0.4–1.0)	(0.4–1.3)	(0.1-0.7)	(0.0–2.6)	(0.1–1.4)	(0.0-1.4)
IUD ²	15.5%	15.6%	15.1%	16.7%	15.5%	20.4%
	(14.0–16.9)	(13.8–17.4)	(12.4–17.7)	(11.6–21.9)	(12.5–18.6)	(16.7–24.0)
Birth control implant ²	6.1%	5.2%	6.8%	9.1%	5.7%	5.2%
	(5.1–7.1)	(4.0~6.4)	(4.6–9.0)	(5.0–13.2)	(4.0–7.5)	(2.5–8.0)
Birth control shot, patch, or	16.9%	15.5%	17.9%	18.4%	16.8%	11.7%
ring ^z	(15.2–18.6)	(13.6–17.4)	(14.5–21.2)	(12.6–24.2)	(13.2–20.4)	(8.5–14.9)
Hysterectomy ^z	4.4%	4.8%	5.2%	3.2%	3.6%	3.5%
	(3.5~5.3)	(3.7–5.8)	(3.0-7.3)	(0.8–5.6)	(2.2-4.9)	(1.8–5.1)

4.6%

(2.5 - 6.6)

9.5%

(6.8 - 12.2)

8.9%

(4.2 - 13.6)

11.2%

(5.9 - 16.4)

5.0%

(2.8 - 7.1)

9.8%

(7.3 - 12.2)

2.9%

(1.4 - 4.3)

5.1%

(2.8 - 7.3)



Emergency contraceptive²

Other²

Groupe des Services de santé des Forces Canadiennes

4.0%

(3.0 - 5.1)

10.8%

(9.2 - 12.4)

4.8%

(3.7 - 5.8)

10.1%

(8.7 - 11.4)

Canadian Forces Health Services Group

Google trend data extract (29JAN23) search topic: intrauterine device, 5 years, CAN vs USA



Intrauterine device: (United States)

Intrauterine device: (Canada)

Birth control - Explore - Google Trends





US National Center for Health Statistics



Health Services Group

Groupe des Services de santé des Forces Canadiennes

Data extracted from 2015-2017 National Survey of Family Growth (CDC)

US National Center for Health Statistics



Data extracted from 2015-2017 National Survey of Family Growth (CDC)

US National Center for Health Statistics



RAND study

23.5% of respondents reported discussing LARCs with their PHA provider in the last 12 months. Definition / study differences make other comparisons difficult.



FIGURE 1. Annual prevalence of LARC, SARC, IUD, and implant use, female service members, active component, U.S. Armed Forces, 2016–2020



SARC, short-acting reversible contraceptive; LARC, long-acting reversible contraceptive; IUD, intrauterine device.

Canadian Forces Health Services Group



Groupe des Services de santé des Forces Canadiennes

Data extracted from 2015-2017 National Survey of Family Growth (CDC)

CAF approach -> 2011-2022

TYPE ANALYZED	UNIQUE Rx PER GROUP			
Emergency contraceptive	7			
Implant	1			
Injectable	2			
IUD - Copper	4			
IUD - Hormonal	3			
IUD - Unknown	1			
Oral - Biphasic	1			
Oral - Cyclic	34			
Oral - Extended Cycle	3			
Oral - Progestin only	4			
Oral - Triphasic	5			
Patch	1			
Vaginal Ring	2			
Total Rx Products	68			

Indayo Seasonale Seasonique Jencycla Micronor Movisse Slynd Tri-Cira Tri-Cyclen Tri-Cyclen Lo Tri-Jordyna Triquilar Evra Haloette Nuvaring Marvelon

Backup Plan Onestep Contingency One Ella Next Choice Norlevo Option 2 Option 2 Plan B Nexplanon Depo-Provera Medroxyprogesterone Flexi-T IUD Liberte Mona Lisa Nova-T Jaydess

Kyleena

Mirena

Unspecified IUD Synphasic Alesse Alysena Apri Aviane Brevicon 0.5/35 Brevicon 1/35 Cleo-35 Cyclen Demulen Diane-35 Esme Freya **Generic Diane-35** Linessa Loestrin Lolo

Minestrin Min-Ovral Mirvala Mya Ortho 0.5/35 Ortho 1/35 Ortho 7/7/7 Ortho-Cept Ovima Ovral Portia Select 1/35 Yasmin Yaz Yaz Plus Zamine Zarah

Canadian Forces Health Services Group





CAF Reg F HEC Rx Trends for "new" users - 2011-2022

Canadian Forces Health Services Group



Groupe des Services de santé des Forces Canadiennes

80%

Counts CAF Reg F HEC Rx Trends by CLASS - 2011-2022 *new to MHS users* and "switches"





Canadian Forces

Health Services Group

Externally generalizable?

Comparison (CAF / U.S. Armed Forces) annual prevalence of LARC utilization 2017-2022



Canadian Forces Health Services Group



Discussion

- Universal coverage of active-duty service members does not guarantee access within patient-desired timelines (LARCs)
- Reasonable to consider sub-group analyses conducted/planned in larger population partner nations to CAF
- LARC use (hypothesis generating) -> similar between CAF / US ADSM CAF LARC use only -> 21.4% last 2018-2022 inclusive Increasing proportion of HEC starts are LARC Decreasing number of new HEC starts since 2020
 - ? Pandemic
 - ? Social
 - ? Access component given LARC preference

Canadian Forces Health Services Group



Limitations

- Administrative data source without correlation to primary indication
- Estimated LARC prevalence <u>calculated</u> via combination of licensing length and published probability of continuation for IUD/implants in DoD (AFHSD)
- Impact of no/low-cost public health services within CANADA in the 18-24 ADSM population
 - > Incomplete capture



Canadian Forces

Health Services Group